Ascendis Pharma A/S

Ascendis Pharma A/S announced it will present new clinical data for its hypoparathyroidism and achondroplasia programs at the American Society for Bone & Mineral Research (ASBMR) 2026 meeting. Key presentations include long-term data on TransCon® PTH (palopegteriparatide) demonstrating normalization of bone mass over five years in hypoparathyroidism patients. The company will also share updates on TransCon CNP (navepegritide) for achondroplasia, including data on growth and physical functioning in children. Ascendis highlighted the potential of its TransCon-based therapies to improve patient health and quality of life.

Ascendis Pharma reported strong second quarter 2026 financial results, with total product revenue increasing 105% year-over-year to €315 million. The company achieved an operating profit of €220 million and a net profit of €207 million, or €2.83 per diluted share. Key drivers included robust sales of YORVIPATH®, SKYTROFA®, and YUVIWEL®, along with the sale of a Rare Pediatric Disease Priority Review Voucher for €158 million. Ascendis also settled all outstanding convertible notes and made significant progress in its pipeline, including completing enrollment for the pivotal infant reACHin Trial.

Ascendis Pharma reported a strong financial performance for Q2 and H1 2026, swinging from a net loss to a substantial net profit. Q2 2026 net profit reached €206.97 million on revenue of €339.28 million, driven by the U.S. FDA approval of YUVIWEL® (navepegritide) and the subsequent sale of a Rare Pediatric Disease Priority Review Voucher for $187.5 million. The company also completed the redemption of $575 million in convertible notes and executed a $120 million share repurchase program during the period.

Ascendis Pharma reported strong second-quarter 2026 financial results, with product revenue surging 105% year-over-year to €315 million, driven by robust demand for YORVIPATH®, SKYTROFA®, and YUVIWEL®. The company achieved an operating profit of €220 million and a net profit of €207 million. Key business updates include the settlement of all convertible notes and inclusion in multiple Russell U.S. Indexes.

Ascendis Pharma A/S's board of directors granted an aggregate of 15,060 warrants to certain employees on August 11, 2026. Each warrant confers the right to subscribe for one ordinary share at an exercise price of $254.57. The warrants will vest over time, with 25% vesting after one year and the remainder monthly thereafter, subject to continued service. The company also amended its Articles of Association in connection with this grant.

Ascendis Pharma provided positive updates on its achondroplasia programs, including durable growth and improved body proportionality from the combination therapy (TransCon CNP + TransCon hGH) in the COACH trial, with 100% patient retention at Week 78. The TransCon CNP monotherapy also demonstrated durable height improvements and benefits beyond height in the ApproaCH trial over 104 weeks, with a favorable safety profile. The company also reported progress on the US launch of YUVIWEL (navepegritide), with over 170 patient enrollments and 65% reimbursement approval, and anticipates an EU regulatory decision for TransCon CNP monotherapy in Q4 2026.

Ascendis Pharma provided positive updates on its achondroplasia programs, highlighting durable and unprecedented growth from its TransCon CNP and TransCon hGH combination therapy at Week 78. Monotherapy data for TransCon CNP also showed sustained improvements in height and body proportionality at Week 104. The company completed enrollment for its pivotal reACHin Trial and reported strong U.S. uptake for YUVIWEL, with over 170 patient enrollments and more than 65% approved for reimbursement.

Ascendis Pharma A/S's board of directors granted 14,060 warrants to certain employees on July 14, 2026. Each warrant allows subscription for one ordinary share at an exercise price of $265.57, matching the closing price on the grant date. The warrants vest 25% after one year, with the remaining 75% vesting monthly over three years, subject to continued service. Following this grant, 1,539,503 additional warrants are available for future grants.

Ascendis Pharma A/S announced new radiographic data from Week 104 of the pivotal ApproaCH Trial for once-weekly TransCon CNP (navepegritide) in children with achondroplasia. The data demonstrated continued improvements in lower extremity alignment, including tibial-femoral angle (TFA), through up to two years of treatment. Improvements in annualized growth velocity and ACH-specific height Z-score were also maintained. TransCon CNP was generally well tolerated, with a low rate of mild injection site reactions and no symptomatic hypotension or acceleration of bone age.

Ascendis Pharma announced new radiographic data from the pivotal ApproaCH Trial of once-weekly TransCon CNP in children with achondroplasia. The data, presented at ICCBH 2026, showed continued improvements in lower extremity alignment, specifically tibial-femoral angle (TFA), through up to two years of treatment (Week 104). Greater improvements were observed in children with preexisting genu varum, reinforcing the drug's potential to address serious complications of skeletal dysplasia. TransCon CNP was generally well tolerated, and the drug was approved by the US FDA in February 2026.